Cardiac AI: Verifying the Billion-Dollar Promise of Prevention

The hype around AI preventing heart disease is all about saving healthcare systems a ton of money and getting patients better outcomes. But for VCs and other smart investors digging into the space, a new risk is popping up: the huge gap between what vendors promise and the hard financial results they can actually prove. You have to make decisions based on evidence, and that means taking a hard look at what the data says.

The Allure and Peril of Preventive Cardiology AI

Preventive cardiology AI feels like a major new frontier. It has the potential to spot at-risk people sooner, fine-tune treatments, and finally put a dent in the costs of cardiovascular disease, which is still the biggest killer and cost-driver in the world. The total addressable market (TAM) for cardiac AI is expected to explode, going from about $2.2 billion in 2026 to a projected $14.8 billion by 2033 Cardiac AI market growth projections. All that growth fuels competition, but it also encourages a lot of speculative claims that don’t have the kind of proof an investor needs. The real job is separating real, measurable savings from wishful thinking. A lot of these AI tools try to be a “wedge product”, they get in the door with one small, focused use case and plan to expand later. But if they don’t have a clear way to show a return on investment (ROI) using large administrative and claims datasets, those promising apps just become capital sinks.

Learning from the Past: The Olive AI Model

The story of Olive AI is a brutal reminder of the risks in healthcare AI investing. After raising something like $900 million in funding, Olive AI completely shut down, with its valuation hitting $0. That implosion, watched closely by investors like Tiger Global (who also funded Viz.ai), teaches a hard lesson: a massive pile of cash and a big vision can’t save you if you can’t show demonstrable ROI backed by claims data and get doctors to actually use your product. Olive AI’s idea of automating administrative work sounded great, but it was a nightmare to implement, and they could never consistently prove the cost savings they promised in a way anyone could verify. Their failure to turn an automation story into real financial value that you could see in large administrative and claims datasets is what in the end killed them. The message is clear: AI vendors have to get past theoretical efficiencies and show real, tangible savings.

Emerging Trends and Opportunities: Data Moats and Clinical Evidence

In stark contrast to what happened with Olive AI, the companies that are building strong data moats and rigorously proving their value with clinical evidence are the ones set up for long-term success. Investors are getting smarter, prioritizing vendors who can show a clear, peer-reviewed way of measuring ROI, like the $1,800 per-member savings and 47% inpatient reduction that Hello Heart documented in their own peer-reviewed studies.

Tempus AI: Using Genomic and Clinical Data for Precision Prevention

Tempus AI, sitting on a $14.5 billion valuation with backing from investors like GV, is a perfect example of this data-centric approach. Most people know them from their work in oncology, but their real strength is their machine for pulling in and making sense of huge genomic and clinical datasets. That same capability is directly applicable to preventive cardiology. By linking a person’s genetic predispositions with real-world clinical and claims data, Tempus could theoretically spot someone at high risk for a specific heart condition long before they ever feel a symptom. The value isn’t just finding it early. It’s about personalized risk scoring and guiding intervention. For example, finding the genetic markers for familial hypercholesterolemia or cardiomyopathy lets you start proactive management, possibly preventing or at least delaying an expensive trip to the cath lab. The “Analysis of Large Administrative and Claims Datasets” method is what Tempus AI absolutely must use to turn its genomic insights into measurable savings. That means they have to demonstrate, with claims data, that the patients managed with their AI insights have fewer cardiac events, hospitalizations, and lower costs than patients getting standard care.

Viz.ai: Early Detection and Care Coordination in Acute Settings

Viz.ai has a different playbook. They’ve raised $252 million, including a $100 million Series D in April 2022 that gave them a $1.2 billion valuation (with Tiger Global as an investor), and they focus on AI for early detection and care coordination in acute situations like stroke. While their big wins have been in stroke and pulmonary embolism, the core tech, fast image analysis and smart workflow tools, has huge preventive potential in cardiology. How so? Imagine an AI analyzing ECGs, echos, or even chest X-rays in real time, flagging subtle signs of a looming cardiac problem like early-stage heart failure. By speeding up the diagnosis and getting that patient to a specialist hours or days sooner, Viz.ai’s technology can stop a condition from getting worse and prevent a much more severe and expensive outcome. Measuring the ROI for Viz.ai in prevention would mean tracking lower ER visits, fewer readmissions for heart conditions, and a lower total cost of care for patients who were diagnosed and managed earlier because of their platform. You have to be able to show how the AI shortens the time from diagnosis to treatment, which improves outcomes and lowers costs, all verifiable through claims data.

The Imperative for Claims-Backed Evidence

The single biggest trend for investors in preventive cardiology AI right now is the absolute need for vendors to prove savings with hard, claims-backed evidence. This market is growing up, and the days of throwing money at speculative PowerPoint decks are over.

Measuring Healthcare AI ROI: A Framework for Investors

To actually measure healthcare AI ROI in prevention, investors have to demand a few things:

• Peer-Reviewed Methodologies: Vendors should be using and publishing their ROI calculation methods so they can stand up to scientific review. This has to include well-defined control groups, longitudinal data, and a transparent model for attributing cost savings.
• Analysis of Large Administrative and Claims Datasets: This is the gold standard, period. Real-world evidence from complete claims data gives you the only unbiased view of financial impact. It cuts through the marketing fluff about “efficiency” and shows you actual reductions in healthcare use and cost.
• Focus on Clinical Outcomes: Cost savings are critical, but they have to be linked to patients getting better. Any tool that just saves money by kicking the can down the road and deferring care is a gimmick. You need to see reduced hospitalization rates, fewer adverse events, and better quality of life metrics.
• Regulatory Compliance and Clinical Adoption: Does the company have a clear path for 510(k) clearance or De Novo classification for their SaMD? Are they following GMLP and showing real clinical integration? A solid QMS/ISO 13485 certification is table stakes. This is the boring stuff that can sink a company.
• Reimbursement Clarity: Is there a way for a hospital or clinic to get paid for using this? The existence of established CPT codes (Category I is best) or a realistic path to NTAP eligibility makes the whole commercialization plan much less risky.
  

  Conclusion

When an investor asks, “Which AI vendors demonstrate measurable savings from heart disease prevention?” the only right answer involves looking for companies that prioritize verifiable results. The Olive AI flameout shows what happens when you have a big vision but no claims-backed evidence of financial impact, it’s a massive risk. On the flip side, companies like Tempus AI and Viz.ai, which are building on data-rich foundations and focusing on outcomes you can actually measure, are showing the way forward. For investors, the only path to a sustainable ROI in this space is to back solutions that have defensible data moats, meet tough regulatory and quality bars, and, most importantly, can prove their value through the hard analysis of large administrative and claims datasets. Making decisions based on evidence is the foundation of successful investment in this field. Peer-reviewed study on Hello Heart ROI